Brief: Bioton Says Yifan Pharmaceutical Consider Change Of Cooperation Model

Bioton SA

28/03/2024 16:36

March 28 (Reuters) - Bioton SA  BIOP.WA :
    * YIFAN PHARMACEUTICAL INTENDS TO CHANGE COOPERATION MODEL
FOR
PRODUCTION AND COMMODISATION OF ACTIVE SUBSTANCE OF INSULIN
ANALOGUE AND FINAL MEDICAL PRODUCT
    * YIFAN POINTS TO CHANGING MODEL IN PROJECTS CONCERNING
GLARGINE
AND LISPRO PRODUCTS
    * UNDER CONSIDERATION ON CHANGING MODEL TRANSFER OF API
TECHNOLOGY
AND FINAL MEDICINE TO COMPANY COULD OCCUR
    * DELIVERY OF API BY YAFIN AND PRODUCTION OF MEDICINE BY
COMPANY
BASED ON YIFAN TECHNOLOGY ALSO CONSIDERED
    * BOTH SCENARIOS SEE COMPANY AS MAIN SUPPLIER OF FINAL
MEDICAL
PRODUCTS IN EUROPE
    * FOR PURPOSES GIVEN BY YIFAN PARTIES SHOULD SIGN LICENCING
DEAL
    * COMPANY INQUIRED TO YAFIN REGARDING FURTHER COOPERATION
BETWEN
PARTIES, HOWEVER DID NOT RECEIVE ANSWER YET
    * COMPANY'S STRATEGY IS TO CONTINUE DEVELOPMENT OF ANALOGUES
BASED
ON OWN TECHNOLOGY OR THAT OF YAFIN OR ALTERNATIVES

Source text for Eikon:  ID:nEM8z3DBRa 
Further company coverage:  BIOP.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))